Perifosine News and Research

RSS

Perifosine is a substance that is being studied in the treatment of cancer. Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.

18 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Aeterna Zentaris Inc. today announced that Johanna Bendell, MD, Director of Gastrointestinal Cancer Research and Associate Director of Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, presented Phase 3 results for perifosine in refractory colorectal cancer yesterday, at the American Society of Clinical Oncology (ASCO) Annual Meeting which is being held in Chicago.

4 Jun 2012

Study provides novel mechanism of action of anti-cancer compound: perifosine

Aeterna Zentaris Inc. today announced that an article published in the May 2012 issue of Plos One, outlines a novel mechanism of action of the Company's oral anti-cancer compound, perifosine, which could provide a rationale for a novel approach to the treatment of Malignant Pleural Mesothelioma (MMe), an aggressive type of cancer associated with exposure to asbestos.

2 Jun 2012

Keryx, Aeterna Zentaris execute perifosine license termination and technology transfer agreement

Keryx Biopharmaceuticals, Inc. today announced that the Company and Aeterna Zentaris Inc. have executed a License Termination and Technology Transfer Agreement, whereby the KRX-0401 (perifosine) license agreement has been terminated and all license rights have reverted back to Aeterna Zentaris.

7 May 2012

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

3 Apr 2012

$Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint$

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris Inc. today announced that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

2 Apr 2012

$Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan$

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan

Aeterna Zentaris Inc. today announced that its Japanese partner, Yakult Honsha, has initiated a Phase 1/2 trial in Japan to assess the safety and efficacy of the Company's PI3K/Akt inhibitor, perifosine, in combination with chemotherapeutic agent, capecitabine, in patients with refractory advanced colorectal cancer ("CRC").

4 Jan 2012

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

20 Sep 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

Keryx reports net loss of $3.1 million for second quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease, today announced its results for the second quarter ended June 30, 2011.

8 Aug 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine, in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

12 Jul 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011